FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
• Relapsed or refractory DLBCL presents significant treatment challenges.
• Limited effective options exist for patients progressing after multiple lines of therapy.

Purpose of the Study:

• To evaluate the efficacy and safety of selinexor as a monotherapy for adult patients with relapsed or refractory DLBCL.
• To determine the objective response rate (ORR) and duration of response (DOR).

Main Methods:

• A multicenter trial (SADAL) assessed selinexor monotherapy in 134 patients with DLBCL previously treated with 2-5 systemic regimens.
• Efficacy endpoints (ORR, DOR) were assessed by an independent review committee using Lugano criteria.
• Safety was evaluated based on adverse event reporting.

Main Results:

• Selinexor demonstrated an ORR of 29% (13% complete response) in patients with relapsed/refractory DLBCL.
• Responses lasted at least 6 months in 38% of responders.
• Common toxicities included gastrointestinal (80%), hyponatremia (61%), and central neurological (25%).

Conclusions:

• Selinexor is an FDA-approved accelerated option for third-line or later treatment of relapsed/refractory DLBCL.
• Management of selinexor-related toxicities requires close monitoring and supportive care.
• Postmarketing studies will explore reduced dosages and further clinical benefits.